Patents by Inventor John Knopf

John Knopf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GDF3 propeptides and related methods
    Patent number: 7465706
    Abstract: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: December 16, 2008
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ALK7 and myostatin inhibitors and uses thereof
    Patent number: 7456149
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: November 25, 2008
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • BMP-3 antibodies and related methods
    Publication number: 20080241164
    Abstract: The present invention provides compositions and methods for promoting bone growth. The present invention also provides methods of screening compounds that modulate BMP-3A or BMP-3B activity. The compositions and methods provided herein are useful in modulating bone growth.
    Type: Application
    Filed: November 19, 2007
    Publication date: October 2, 2008
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ALK1 receptor and ligand antagonist and uses thereof
    Publication number: 20080175844
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: November 2, 2007
    Publication date: July 24, 2008
    Applicant: Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Robert Scott Pearsall, Ravindra Kumar, Jasbir Seehra
  • Tgf Derepressors and Uses Related Thereto
    Publication number: 20080119396
    Abstract: The application is directed to TGF analogs/derepressors that bind to and neutralize cystine knot-containing BMP antagonists—such as the CAN subfamily of Cystine-knot proteins including sclerostin. The subject TGF derepressors can be prepared as substantially pyrogen-free pharmaceutical compositions for administration to mammals, in treating diseases such as bone diseases including osteoporosis, and any conditions with lesser-than-desired amount of BMP activity.
    Type: Application
    Filed: May 27, 2005
    Publication date: May 22, 2008
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Cerberus/Coco derivatives and uses thereof
    Patent number: 7316998
    Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: January 8, 2008
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Activin-ActRIIa antagonists and uses for promoting bone growth
    Publication number: 20070249022
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: November 22, 2006
    Publication date: October 25, 2007
    Inventors: John Knopf, Jasbir Seehra
  • GDF3 propeptides and related methods
    Publication number: 20070172481
    Abstract: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3.
    Type: Application
    Filed: March 21, 2007
    Publication date: July 26, 2007
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Lefty, Lefty derivatives and uses thereof
    Publication number: 20070042958
    Abstract: The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders.
    Type: Application
    Filed: June 30, 2006
    Publication date: February 22, 2007
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • IL-13 binding agents
    Publication number: 20060073148
    Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.
    Type: Application
    Filed: June 17, 2005
    Publication date: April 6, 2006
    Inventors: Lioudmila Tchistiakova, Marion Kasaian, Debra Donaldson, Xiang-Yang Tan, Davinder Gill, Macy Jin, Bruce Jacobson, Samuel Goldman, John Knopf, Angela Widom
  • ActRII receptor polypeptides, methods and compositions
    Publication number: 20060068468
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
    Type: Application
    Filed: July 25, 2005
    Publication date: March 30, 2006
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • GDF3 propeptides and related methods
    Publication number: 20060030520
    Abstract: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3.
    Type: Application
    Filed: June 24, 2005
    Publication date: February 9, 2006
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ALK7 and myostatin inhibitors and uses thereof
    Publication number: 20060030522
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Application
    Filed: March 2, 2005
    Publication date: February 9, 2006
    Inventors: John Knopf, Jasbir Seehra
  • Cerberus/Coco derivatives and uses thereof
    Publication number: 20060025340
    Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
    Type: Application
    Filed: May 27, 2005
    Publication date: February 2, 2006
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • BMP10 propeptides and related methods
    Publication number: 20060024783
    Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.
    Type: Application
    Filed: May 12, 2005
    Publication date: February 2, 2006
    Applicant: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, John Knopf
  • Cytosolic phospholipase A-gamma enzymes and polynucleotides encoding same
    Patent number: 6979565
    Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
    Type: Grant
    Filed: July 8, 2002
    Date of Patent: December 27, 2005
    Assignee: Genetics Institute, LLC
    Inventors: Chuanzheng Song, Ronald Kriz, John Knopf
  • BMP-3 propeptides and related methods
    Publication number: 20050272653
    Abstract: The present invention provides compositions and methods for promoting bone growth. The present invention also provides methods of screening compounds that modulate BMP-3A or BMP-3B activity. The compositions and methods provided herein are useful in modulating bone growth.
    Type: Application
    Filed: March 28, 2005
    Publication date: December 8, 2005
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Cytosolic phospholipase A2-Gamma enzymes and polynucleotides encoding same
    Publication number: 20050233434
    Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
    Type: Application
    Filed: June 20, 2005
    Publication date: October 20, 2005
    Applicant: Genetics Institute L.L.C.
    Inventors: Chuanzheng Song, Ronald Kriz, John Knopf
  • CYTOSOLIC PHOSPHOLIPASE A2-GAMMA ENZYMES AND POLYNUCLEOTIDES ENCODING SAME
    Publication number: 20050142651
    Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
    Type: Application
    Filed: July 8, 2002
    Publication date: June 30, 2005
    Applicant: Genetics Institute L.L.C.
    Inventors: Chuanzheng Song, Ronald Kriz, John Knopf
  • Cytosolic phospholipase A2-gamma enzymes and polynucleotides encoding same
    Patent number: 6440683
    Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
    Type: Grant
    Filed: February 8, 1999
    Date of Patent: August 27, 2002
    Assignee: Genetics Institute L.L.C.
    Inventors: Chuanzheng Song, Ronald Kriz, John Knopf